BRCA1 and breast cancer: Our in vivo study shows that the combined treatment with GSK126 and AZD1390 confers stronger anti-tumor activity than either inhibitor alone in BRCA1-deficient mammary tumors in mice, although the effect on progression-free survival was not strong.